HomepageBIOCON • NSE
add
Biocon
Vorige slotkoers
₹ 364,45
Dag-range
₹ 366,50 - ₹ 373,65
Jaar-range
₹ 244,55 - ₹ 404,70
Beurswaarde
445,99Â mld. INR
Gem. volume
5,56Â mln.
Koers/winst
55,37
Dividendrendement
0,13%
Primaire beurs
NSE
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(INR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 38,56Â mld. | -2,47% |
Bedrijfskosten | 21,36Â mld. | -3,34% |
Netto inkomsten | 251,00Â mln. | -96,20% |
Netto winstmarge | 0,65 | -96,11% |
Winst per aandeel | 0,13 | -97,54% |
EBITDA | 7,42Â mld. | -5,55% |
Effectief belastingtarief | 47,98% | — |
Balans
Totale activa
Totale passiva
(INR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | — | — |
Totale activa | — | — |
Totale passiva | — | — |
Totaal aandelenvermogen | — | — |
Uitstaande aandelen | 1,20 mld. | — |
Koers-boekwaardeverhouding | — | — |
Rendement op activa | — | — |
Rendement op kapitaal | 2,08% | — |
Kasstroom
Nettomutatie in liquide middelen
(INR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 251,00Â mln. | -96,20% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Opgericht
1978
Hoofdvestiging
Website
Werknemers
16.315